Výsledky vyhledávání - "F Carpagnano"

Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection

Autor: DF Bavaro, L Diella, AG Solimando, S Cicco, E Buonamico, C Stasi, M Ciannarella, M Marrone, F Carpagnano, O Resta, GE Carpagnano, VO Palmieri, A Vacca, M Dell’Aera, A Dell’Erba, G Migliore, M Aricò, A Saracino

Publikováno v: Pathogens and global health. 116(5)

The early administration of anti-SARS-CoV-2 monoclonal antibodies (mAb) could decrease the risk of severe disease and the need of inpatients care. Herein, our clinical experience with Bamlanivimab/Etesevimab for the treatment of early SARS-CoV-2 infe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f512c102022097c7727a35f3428b44af
https://pubmed.ncbi.nlm.nih.gov/35138229

Zobrazit plný text záznamu

Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer

Autor: S. Mancarella, F. Carpagnano, N. Panza, Domenico Sambiasi, Michele Guida, Nicola Silvestris, M. De Lena, E. Crucitta, Vito Lorusso

Publikováno v: Annals of Oncology. 13:1862-1867

Background The aim of our study was to determine the maximum tolerated dose of paclitaxel combined with a fixed dose of gemcitabine and vinorelbine in the treatment of non-small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046b983cd6e567ce0adb9d9c66c00417
https://doi.org/10.1093/annonc/mdf308

Zobrazit plný text záznamu

Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC)

Autor: Lorusso, M Cisternino, F Carpagnano, M Guida, M Delena, A Latorre, G diRienzo, M. Brandi, R Ricco, Annamaria Catino, S Parisi

Publikováno v: Scopus-Elsevier

Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/ m(2)/i.v./dl), ifosfamide (4,000 mg/m(2)/i.v./dl) and vinorelbine (30 mg/m(2)/i.v./dl) plus G-CSF 300 mu g/s.c. on days 7-12 every 14 days f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3b1bca731ce259851fc9454c1ec411
https://pubmed.ncbi.nlm.nih.gov/21544412

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(8)

Because both cisplatin-paclitaxel and cisplatin-gemcitabine combinations are generally considered to be among the most active regimens in non-small-cell lung cancer (NSCLC) patients, this study aimed to determine the maximum-tolerated dose (MTD) of p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b04f84c52a4b0ef5a0bebe8b804ffb97
https://pubmed.ncbi.nlm.nih.gov/10561293

Zobrazit plný text záznamu

Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group

Autor: Luigi Maiorino, F. Carpagnano, Giuseppe Frasci, Pasquale Comella, Domenico Bilancia, N. Panza, Michele Di Natale, Mario De Lena, Andrea Bianco, Giuseppe Comella, R. Cioffi, L. Manzione, Giuseppe De Cataldis, Carmen Pacilio, Gaetano Di Rienzo, G.P. Nicolella, Vito Lorusso

Publikováno v: Journal of Clinical Oncology. 17:1526-1526

PURPOSE: In a previous phase I study cisplatin (CDDP), gemcitabine (GEM), and vinorelbine (VNR) combination therapy was safe and very active in patients with non–small-cell lung cancer (NSCLC). This study was aimed at better defining the activity a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94d494bfe4db6c1d25eef0f9f0ef2cee
https://doi.org/10.1200/jco.1999.17.5.1526

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association

Autor: F. Carpagnano, M. Delena, A. Legroumellec, Jean-Yves Douillard, Rafael Rosell, Antoni Torres

Publikováno v: Journal of Clinical Oncology. 23:7013-7013

7013 Background: Adjuvant chemotherapy demonstrated a 5–15% benefit in 5-year survival in the IALT, JBR10 and CALGB9633 trials. However, other trials were negative (ALPI, ECOG 3590) and the role of chemotherapy for each disease stage has not yet be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3eac6399613ef6275df31ff2a2ee30c5
https://doi.org/10.1200/jco.2005.23.16_suppl.7013

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání